Yam, Charmaine, Merlo, Daniel, Stankovich, Jim, Darby, David, Gresle, Melissa, Kalincik, Tomas, Kilpatrick, Trevor J., Lechner-Scott, Jeanette, Taylor, Bruce, Barnett, Michael, Butzkueven, Helmut, van der Walt, Anneke. Elsevier; 2020. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.

Lechner-Scott, Jeannette, Agland, Susan, Allan, Michelle, Darby, David, Diamond, Keri, Merlo, Daniel, van der Walt, Anneke. Elsevier; 2023. Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective.

Foong, Yi Chao, Merlo, Daniel, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria, Gresle, Melissa, Butzkueven, H, van der Walt, A, Zhu, C, MSBASE study group,, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan. BMJ Group; 2024. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.

Binder, Michele D., Fox, Andrew D., Laverick, Louise, Foo, Grace, Fabis-Pedrini, Marzena J., Spelman, Timothy, Jordan, Margaret A., Baxter, Alan G., Foote, Simon, , , , Merlo, Daniel, , , , , , , , , , Lechner-Scott, Jeannette, Johnson, Laura J., , , , , , Moscato, Pablo, Scott, Rodney, , , , Giuffrida, Sarah E., , Calvert, Rainer, Akkermann, Rainer, Ma, Gerry Z. M., Perera, Ashwyn A., Gresle, Melissa M.. Public Library of Science (PLoS); 2016. Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*15:01 status.

Merlo, Daniel, Stankovich, Jim, Darby, David, Butzkueven, Helmut, Van der Walt, Anneke, Bai, Claire, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce. Wolters Kluwer Health; 2021. Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis.

Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.

Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Simpson-Yap, Steve, Butzkueven, Helmut, van Der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce V., Kalincik, Tomas, Kilpatrick, Trevor. Wiley-Blackwell; 2025. Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis.

Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Butzkueven, Helmut, van der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce, Kalincik, Tomas, Kilpatrick, Trevor. Wiley-Blackwell Publishing Ltd.; 2024. Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.